For Investors

Draft Resolutions of the Annual General Meeting of Shareholders of JSC Olainfarm to be Held on June 7th, 2016

on 24 gegužės, 2016 Komentavimas išjungtas įraše Draft Resolutions of the Annual General Meeting of Shareholders of JSC Olainfarm to be Held on June 7th, 2016
  1. Report of the Board on results of operations in 2015.

Draft resolution:
To take notice of the Report of the Board on results of operations in 2015.

 

  1. Report of the Council on results of operations in 2015.

Draft resolution:
To take notice of the Report of the Council on results of operations in 2015.

 

  1. Report of the Auditing Committee on activities in 2015.

Draft resolution:
To take notice of the Report of the Auditing Committee on activities in 2015.

 

  1. Approval of the Audited Consolidated Annual Report of Group and Parent Company for 2015.

Draft resolution:
To approve the Audited Consolidated Annual Report of JSC Olainfarm group and of Parent Company for 2015.

 

  1. Distribution of profit of 2015.

Draft resolutions:
5.1. To use part of the year 2015 profit of JSC Olainfarm in amount of 2 549 399.12 euros to pay dividends to shareholders of JSC Olainfarm, (ISIN code of the shares LV0000100501) paying 0.181 euros per one share. Part of the profit in amount of 12 016 600.88 euros to retain undistributed and to reinvest in development of JSC Olainfarm.
5.2. Set September 14, 2016, as a record date for dividends and September 21, 2016, as the date of payment of dividends.

 

  1. Report of the Board on budget and on planned operations in 2016.

Draft resolution:
To take notice of Report of the Board on budget and on planned operations in 2016, which include Parent Company’s unconsolidated turnover forecast for 2016 in amount of 86 million euro, and JSC Olainfarm consolidated turnover forecast for 2016 in amount of 100 million euro. Forecast of unconsolidated profit of JSC Olainfarm is 9 million euro, but consolidated profit is 10 million euro.

 

  1. Election of the Certified Auditor for 2016.

Draft resolutions:
7.1. to elect SIA Ernst & Young Baltic (license No.17, unitary registration No. 40003593454) to be the certified auditor of JSC Olainfarm in 2016.
7.2. to set 43 300 EUR as the total remuneration of certified auditor for 2016.

 

  1. Election of the Auditing Committee.

Draft resolutions:
8.1. to elect Viesturs Gurtlavs to be the sole member of the Auditing Committee.
8.2. to set the total monthly remuneration of the Auditing Committee at 4800 euros.

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

read more
Draft Resolutions of the Annual General Meeting of Shareholders of JSC Olainfarm to be Held on June 7th, 2016

Sales of Olainfarm in April Reach 8.82 Million Euros

on 16 gegužės, 2016 Komentavimas išjungtas įraše Sales of Olainfarm in April Reach 8.82 Million Euros

According to preliminary consolidated results of JSC Olainfarm for April 2016, sales of the company have reached 8.82 million euros, which represents a reduction by 4% compared to April of 2015. The biggest sales increase was achieved in Italy, where sales grew by 388%. Sales to Uzbekistan grew by 191%; sales to Turkmenistan grew by 77% while sales to Lithuania grew by 69%. The major sales markets in April were Russia, Latvia, Ukraine, Belarus and Uzbekistan.

April 2016, consolidated sales Sales, thsnd. EUR Changes to April, 2015 Share in total sales
Russia 2 969 -15% 34%
Latvia 2 160 7% 24%
Ukraine 1 285 31% 15%
Belarus 669 -9% 8%
Uzbekistan 426 191% 5%
Italy 284 388% 3%
Turkmenistan 172 77% 2%
Kazakhstan 98 -51% 1%
Lithuania 88 69% 1%
Kyrgyzstan 78 -39% 1%
Other 593 -51% 7%
Total 8 823 -4% 100%

 

Sales of chain of pharmacies of Latvijas aptieka Ltd., fully owned by JSC Olainfarm were 1.58 million euros, which represents an increase by 13% compared to April of 2015. Sixty-one pharmacies were operating during this period. Sales of Silvanols Ltd. during April of 2016 were 0.39 million euros, which represents an increase by 18% compared to April of last year. During April of this year, Silvanols Ltd. sold its products in six European countries, and, with a help of JSC Olainfarm, also to Albania, Kosovo and Azerbaijan.

In four months of 2016, according to preliminary consolidated results, consolidated sales of JSC Olainfarm were 35.05 million euros, which represents a reduction by 5% compared to the same period of 2015. The biggest sales increase was achieved in Italy, where sales grew by 328%. Sales to Uzbekistan grew by 158%, sales to Turkmenistan grew by 133% while sales to Belarus grew by 51%. Major sales markets in four months of 2016 were Russia, Latvia, Ukraine and Belarus.

4 months of 2016, consolidated sales Sales, thsnd. EUR Changes to 4 months of 2015 Share in total sales
Russia 9 274 -32% 26%
Latvia 8 780 11% 25%
Ukraine 6 274 44% 18%
Belarus 3 696 51% 11%
UK 939 12% 3%
Uzbekistan 904 158% 3%
Kazakhstan 667 -24% 2%
Turkmenistan 654 133% 2%
Italy 530 328% 2%
The Netherlands 473 -83% 1%
Other 2 856 -9% 8%
Total 35 047 -5% 100%

 

During 4 months of 2016, sales of pharmacy chain of Latvijas aptieka Ltd. were 6.6 million euros, which represents an increase by 18% compared to the same period of 2015. Sales of Silvanols Ltd. during this 4 months period were 1.6 million euros, which represents an increase by 14% compared to 2015, when its sales during four months were 1.4 million euros. Products of Silvanols Ltd. were sold to nine European countries and with the help from JSC Olainfarm to Albania, Kosovo, Azerbaijan and Belarus.

According to unconsolidated preliminary results, sales of JSC Olainfarm during April 2016 reached 7.67 million euros, which represents a reduction by 5% compared to the same period of last year. The biggest sales increase was achieved in Italy, where sales increased by 388%. Sales to Uzbekistan increased by 191%, but sales to Turkmenistan increased by 77%. The major sales markets were Russia, Ukraine, Latvia, Belarus and Uzbekistan. During April 2016, JSC Olainfarm sold its products to 27 countries in three continents.

April 2016, unconsolidated sales Sales, thsnd. EUR Changes to April, 2015 Share in total sales
Russia 2 969 -15% 39%
Ukraine 1 285 31% 17%
Latvia 1 103 2% 14%
Belarus 669 -9% 9%
Uzbekistan 426 191% 6%
Italy 284 388% 4%
Turkmenistan 172 77% 2%
Kazakhstan 98 -51% 1%
Kyrgyzstan 78 -39% 1%
Moldova 72 31% 1%
Other 508 -51% 7%
Total 7 665 -5% 100%

 

According to unconsolidated preliminary results sales of JSC Olainfarm in four months of 2016 were 30.39 million euros, which represents a reduction by 7% compared to the same period of 2015. The biggest sales increase was achieved in Italy, where sales grew by 328%. Sales to Uzbekistan grew by 158%; sales to Turkmenistan grew by 133%, while sales to Belarus grew by 51%. Major sales markets of JSC Olainfarm in four months of 2016 were Russia, Ukraine, Latvia and Belarus. In total, during four months of 2016 products of JSC Olainfarm were sold to 37 countries in three continents.

4 months of 2016, unconsolidated sales Sales, thsnd. EUR Changes to 4 months of 2015 Share in total sales
Russia 9 274 -32% 31%
Ukraine 6 190 42% 20%
Latvia 4 650 9% 15%
Belarus 3 696 51% 12%
UK 939 12% 3%
Uzbekistan 904 158% 3%
Kazakhstan 667 -24% 2%
Turkmenistan 654 133% 2%
Italy 530 328% 2%
The Netherlands 473 -83% 2%
Other 241 -6% 8%
Total 30 387 -7% 100%

 

According to preliminary estimates of JSC Olainfarm, unconsolidated sales of company in 2016 could reach 90 million euros, while consolidated sales are expected to reach 103 million euros. According to preliminary sales figures published here, in four months of 2016, the Company has attained 34% of its target for unconsolidated sales and 34% of its target for consolidated sales.

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

read more
Sales of Olainfarm in April Reach 8.82 Million Euros

Olainfarm Acquires Tonus Elast, Producer of Elastic Medical Products

on 12 gegužės, 2016 Komentavimas išjungtas įraše Olainfarm Acquires Tonus Elast, Producer of Elastic Medical Products

Today, on May 12, 2016, Valerijs Maligins, Chairman of the Board of JSC Olainfarm and Ludmila Cecotkina and Irina Vinvalka, co-owners of Tonus Elast Ltd., signed an agreement whereby Olainfarm acquired 100% shares in the above producer of elastic medical products. Value of the transaction was 14 million euros, and during the few coming days it will be registered in Latvian Company Register. Dace Mihnenoka, Chairwoman of Board of Tonus Elast Ltd. will keep her position.

“We know Tonus Elast very well since 2010, when we were representing them in Ukraine. We appreciated high quality of their products and witnessed considerable demand. It was then when we saw that the company has significant exporting potential to other markets as well and identified it as an acquisition target. Tonus Elast, similarly to Olainfarm has demonstrated significant development over the last several years and we think that with our marketing and expansion experience we can even better utilize potential that Tonus Elast has. And last, but definitely not least, products of Tonus Elast will fit extremely well in pharmacies of Latvijas aptieka chain,” says Valerijs Maligins, Chairman of Olainfarm’s Board.

Ludmila Cecotkina, co-owner of Tonus Elast Ltd. emphasizes: “There was quite a significant interest to acquire Tonus Elast: it was being looked at by companies from Russia, Poland, Germany and Latvia. We are happy that we agreed with Olainfarm, because the company my husband created more than 20 years ago and cherished all this time will be preserved and its development will continue here in Latvia. Olainfarm has proven its ability to successfully develop its daughter companies. We hope, that Tonus Elast, being the youngest of daughters will grow fast and will be even more known to the world than now “.

“By joining the group of Olainfarm Tonus Elast obtains new possibilities for development. That means not only investments, but also experienced colleagues to cooperate with at entering new markets and developing new products and also the feeling of being a part of the Baltic pharmaceutical leadership. More details about the new products that we are working on will be available closer to the end of the year. What I can tell you right now for sure is that we are expecting significant sales growth to Russia and Ukraine in a very near future,” says Dace Mihnenoka, Chairwoman of the Board of Tonus Elast Ltd..

Tonus Elast Ltd. was established in 1995 and is producing elastic medical products from elastic bandages to very complicated corset structures for pregnant and lactating women. Production site of Tonus Elast Ltd. meets all the standards of a modern producer of medical products, which is proven by LVS EN ISO 9001:2009 certificate.

Product portfolio of Tonus Elast Ltd. includes more than 100 different types of products. Best sold of them are bandages and compression products. On average about 11.2 million units per year are produced on production site of Tonus Elast Ltd. in Nica County. About 11% are sold locally in Latvia, while 89% are being exported. The main markets are CIS countries, EU, India and the Middle East. In Latvia, products of Tonus Elast Ltd. are available from company stores in Riga, Liepaja, Daugavpils and Ventspils, as well as in several pharmacies and internet shopping sites.

Tonus Elast Ltd. employs a little more than 200 people, which makes this company the biggest taxpayer and employer in Nica County. According to unaudited reports, in 2015 sales of Tonus Elast Ltd. were 7.3 million euros, while net profit reached 1.7 million euros.

Group of Olainfarm consists from its parent company JSC Olainfarm, pharmacy chain Latvijas aptieka Ltd. and Kiwi Cosmetics Ltd., producer of eco cosmetics. JSC Olainfarm also owns 96.69% shares in Silvanols Ltd., the leading Latvian producer of food supplements.

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

read more
Olainfarm Acquires Tonus Elast, Producer of Elastic Medical Products

Report of the Supervisory Council of JSC Olainfarm to the General Meeting of Shareholders

on 8 gegužės, 2016 Komentavimas išjungtas įraše Report of the Supervisory Council of JSC Olainfarm to the General Meeting of Shareholders

Supervisory Council of JSC Olainfarm has read the Consolidated and Parent Company’s Annual reports for 2015, as well as Independent Auditors’ Report about it. In addition, the Council has assessed financial position of the Company and Operations of the Management Board during this financial year and hence produced this Report.

The Council values very highly the work conducted by Company’s Board during the last year, as it resulted not only in increased sales volumes but also in record high profits. This has all been achieved in times, when economic situation in several markets important for the Company is facing stagnation or even heavy recession. The Council shares the concerns of the Board regarding declining sales in Belarus, which has for many years been one of the most important markets for the company, therefore the Council urges the Board to take all reasonably justified measures to prevent further declining of sales in this country. The Council is satisfied with very successful cooperation of the Company with the World Health Organization and with very good operations of Company in countries of Central Asia. Both these factors have helped the Company to achieve 4% sales growth despite previously mentioned issues in Russia, Ukraine and Belarus.

During 2015 the Council has paid a very close attention to development of several related companies of the Group. The Council would like to particularly emphasize the rapid and positive developments taking place at Silvanols Ltd. during 2015, when this company, possibly for the first time in its history made significant profit from its basic operations. Also, developments at Latvijas aptieka Ltd. are worth noting as this company keeps increasing number of its pharmacies and in 2015 the number was comfortably above 60.

Consolidated profit of the company in 2015 reached 15.3 million euros, but unconsolidated profit reached 14.6 million euros. Both these numbers are the highest in corporate history and are significantly higher than the results of 2014. Both, consolidated and unconsolidated profit targets have been exceeded, but it should however be noted, that positive foreign exchange fluctuations in early months of 2015, when Russian Rouble gained significant strength have contributed to it. The Council has drawn the attention of the Board that in different circumstances the current margins might be difficult to attain.

Relatively small sales growth, instable situation in several important markets, stagnating or even declining sales of some of Company’s main products have made the Council to again stress the necessity to make greater effort to diversify Company’s sales markets or products offered by companies of the Group. The Council will support any reasonable steps contributing to this, including acquisitions of new companies.

The Council is satisfied that the Board kept its promise previously made to shareholders and after the two year dividend break is suggesting that 17.5% of the profit made in 2015 be paid in dividends. The Council suggests that, although the necessity for the Company to make different investments will not diminish, in order to observe the best interests of shareholders, no more dividend breaks are held in future, should that be possible.

During 2015 the Council of the Company has performed its duties and supervised operations of the Company according to legislation, decisions by the general meeting. The Council has approved financial statements and overviewed operations of Company’s management. During the reporting period 18 Council meetings were held. During these meetings, Board reports, Board composition, plans, planned and actual budgets were reviewed. Agenda items of general meeting was pre-approved. Council found no insufficiencies in Boards operations in 2015. The Board has been in constant consultations with the Council and has taken into account all previously mentioned and other recommendations of the Council targeted at safe further development of the Company.

The Council would like to take this opportunity to thank the Board, all employees of the Company and its partners for successful operations in 2015, to congratulate shareholders with record high results of the last year and to wish successful, stable and positively challenging 2016.

Approved by the Council Meeting on May 6, 2016

Chairwoman of the Council                         Valentina Andrejeva

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

read more
Report of the Supervisory Council of JSC Olainfarm to the General Meeting of Shareholders

Proposal of the Management Board of JSC Olainfarm Regarding Distribution of Profit of 2015

on 6 gegužės, 2016 Komentavimas išjungtas įraše Proposal of the Management Board of JSC Olainfarm Regarding Distribution of Profit of 2015

The amount of net profit made by JSC Olainfarm in 2015 is 14 566 000.00 (fourteen million five hundred and sixty six thousand) euros.

Management Board of JSC Olainfarm proposes to use part of the year 2015 profit of JSC Olainfarm in amount of 2 549 399.12 euro to pay dividends to shareholders of JSC Olainfarm (ISIN code of the shares LV0000100501) paying 0.181 euro per one share, but part of the profit in amount of 12 016 600.88 to retain by the company and reinvest into further development of JSC Olainfarm.

read more
Proposal of the Management Board of JSC Olainfarm Regarding Distribution of Profit of 2015

Announcement About Convening of the Annual General Meeting of Olainfarm

on 6 gegužės, 2016 Komentavimas išjungtas įraše Announcement About Convening of the Annual General Meeting of Olainfarm

Management Board of the Joint Stock company Olainfarm (registration number. 40003007246, registered  address: Rupnicu iela 5, Olaine, LV-2114) convenes and announces that the Annual General Meeting of JSC Olainfarm Shareholders will be held on June 7th, 2016 at 11:00 at the  premises of JSC Olainfarm in Olaine, Rupnicu iela 5.

Agenda:

  1.  Report of the Management Board about the results of operations in 2015.
  2.  Report of the Council about the results of operations in 2015.
  3.  Report of the Auditing Committee about 2015.
  4.  Approval of JSC Olainfarm Сonsolidated and Parent Сompany’s Annual Report for year 2015.
  5.  Distribution of profit of 2015.
  6.  Report of the Management Board about the budget and operational plan for 2016.
  7. Elections of the sworn auditor for 2016 and setting of the remuneration for the sworn auditor.
  8. Elections of the Auditing Committee for 2016 and setting of the remuneration of the Auditing  Committee.

Registration of the shareholders will take place on the day of the meeting, i.e. June 7th, 2016 from  10:00 until 10:45 on the venue.

Total number of shares and the total number of the voting shares of JSC Olainfarm is 14 085 078.

Date of the record for participation of the shareholders in the Annual General Meeting of shareholders  of JSC Olainfarm is May 30th, 2016. Only those who are the shareholders at the date of record have  the right to participate in the Annual General Meeting of shareholders on June 7th, 2016, with the  number of shares held by them at the date of record.

Shareholders may participate in the Annual General Meeting of shareholders either in person or  represented through a proxy:

– When registering the shareholders must present either the passport or other  identification document;
– When registering the representatives of the shareholders must present the passport or  other identification document, submit a written power of attorney by the represented shareholder (the  form of the power of attorney is available at JSC Olainfarm web-site  https://lt.olainfarm.com, web-site of the system of Central Storage of Regulated Information http://www.oricgs.lv; and web-site of JSC  NASDAQ OMX Riga http://www.nasdaqomxbaltic.com) or the legal representative has to present a document confirming the authority.

Shareholders have the following rights:

– shareholders that represent at least 1/20 of the capital of the company have the right  to within 7 days after the announcement is published to request the Management Board of JSC Olainfarm  to include additional items in the agenda. Shareholders that request inclusion of additional items in  the agenda of the Annual General Meeting of shareholders must submit to the Management Board of JSC  Olainfarm draft decisions about the issues to be included in the agenda upon their request or  explanations about the item, if no decision is planned;

– within 7 days after the publishing of this announcement, submit draft decisions about  the items of agenda.  Should all submitted draft decisions be reviewed and declined, shareholders may  submit their proposed draft decisions during the Annual General Meeting of Shareholders itself;

– should the shareholder submit an inquiry at least 7 days before the Annual General  Meeting of shareholders, the Management Board shall at least 3 days before the Annual General Meeting  of shareholders provide the requested information about the items included in the agenda. It is a duty  of the Management Board to upon the request of the shareholder provide information about the economic  situation of the company to the extent necessary for objective decision-making of the particular item  on the agenda.

Shareholders may see the draft resolutions of the Annual general Meeting of Shareholders from May 24,  20165 until June 6, 2016 on business days from 09:00 until 16:00 in Olaine, Rupnicu iela 5, in the Legal  division of JSC Olainfarm, if scheduled in advance through telephone + 371 6 7013 870 or on the web  page of JSC Olainfarm  https://lt.olainfarm.com, but on the day of the Annual General Meeting – at the registration desk.

JSC Olainfarm Сonsolidated and Parent Сompany’s Annual Report for year 2015, report of the independent auditors, report of the Council, Corporate governance report and profit distribution proposals are available at web  page of JSC Olainfarm  https://lt.olainfarm.com, web-page of the system of Central Storage of Regulated Information http://www.oricgs.lv and the web page of JSC NASDAQ OMX Riga http://www.nasdaqomxbaltic.com.

Form of Power of Attorney

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

read more
Announcement About Convening of the Annual General Meeting of Olainfarm

Last Year Olainfarm Sets a New Profit Record of 15.3 Million Euros

on 29 balandžio, 2016 Komentavimas išjungtas įraše Last Year Olainfarm Sets a New Profit Record of 15.3 Million Euros

Audited consolidated profit and loss account of JSC Olainfarm for 2015 shows that consolidated net profit was 15.3 million euros. This represents an increase by 25% compared to the net profit of 2014 and by 8% compared to the net profit of 2012, when the previous profit record was set. Parent company’s net profit in 2015 was 14.6 million euros, which represents an increase by 28% compared to the net profit of 2014.

Sales of the Group in 2015 reached 97.4 million euros, which represents an increase by 4% compared to 2014, when sales of the Group were 93.7 million euros and is the highest sales number ever reached by the group so far. Sales of the Parent company in 2015 were 84.7 million euros, which also represents an increase by 4% compared to 2014, when Parent company made sales of 81.6 million euros.

The biggest consolidated sales increase (by 107%) was achieved in The Netherlands, where products for WHO’s Anti-Tuberculosis program are shipped. Sales in Tajikistan increased by 39%, sales to Latvia by 11%. The major sales markets of the Group in 2015 were Russia, Latvia, Ukraine, Belarus and The Netherlands

The biggest Parent company’s sales increase in 2015 was achieved in The Netherlands where sales grew by 107%. Sales to Turkmenistan grew by 46%, but sales to Tajikistan grew by 39%. Significant sales growth has also been achieved in Latvia where sales of the Parent company increased by 25%. Major sales markets of Parent company of JSC Olainfarm in 2015 were Russia, Latvia, Ukraine Belarus and The Netherlands.

The best sold company’s products in 2015 were neurological products “Neiromidin”, “Noofen” and “Adaptol”, anti-tuberculosis product „PASA Sodium”, Antibacterial products „Furamag” and “Furasol”, antiarrhythmic products “Etacizin” and antihistamine product “Fenkarol”.

During the reporting period, registration processes have been launched in Bosnia and Herzegovina, Vietnam, Myanmar; GMP audit by Turkish pharmaceutical authorities has been passed, and bioavailability tests for Turkish registration completed, allowing the Parent company to proceed with registration in Turkey.

New forms have been developed for „Gripoflex 325” (with reduced content of paracetamol), „ACC 200mg” powder, and lactose free „Memantine” tablets of 10mg and 20mg. The work continues at development of new combined prolonged activity form of nitrofurantoin. Two new food supplements have been developed and registered in Baltic countries with urological and hepatological application. Food supplement „Jogurt Babydrops” has been registered in the Baltics and is planned for further registration in 14 countries.

Annual meeting of shareholders of JSC Olainfarm held on June 11, 2015 approved operating plan of the Group for 2015. According to it, sales of the Group in 2015 are planned to be 100 million euros, but the net profit will reach 15 million euros. According to this audited report for 2015, during this period 97.4% of annual sales target and 101.9% of annual profit target is met. The same meeting approved targets for Parent company’s operations, stating that Parent company’s sales target is 87 million euros, but the profit target is 14 million euros. According to these accounts, Parent company met 97.4% of sales target but exceeded its profit target by 4%.

Statement of Financial Position Group Parent company
31.12.2015 31.12.2014 31.12.2015 31.12.2014
EUR ‘000 EUR ‘000 EUR ‘000 EUR ‘000
     ASSETS
NON-CURRENT ASSETS
Intangible assets 20 591 18 848 2 210 2 109
Property, plant and equipment 35 579 34 674 34 047 33 252
Financial assets 4 910 4 234 22 382 19 848
TOTAL NON-CURRENT ASSETS 61 080 57 756 58 639 55 209
CURRENT ASSETS
Inventories 20 990 18 693 18 979 17 172
Receivables 30 487 28 219 31 178 29 077
Cash 5 574 2 055 5 015 1 745
TOTAL CURRENT ASSETS 57 051 48 967 55 172 47 994
TOTAL ASSETS 118 131 106 723 113 811 103 203
EQUITY AND LIABILITIES
EQUITY
Share capital 19 719 20 041 19 719 20 041
Share premium 2 504 2 504 2 504 2 504
Reserves 322 322
Retained earnings 65 773 50 492 65 921 51 355
Non-controlling interests 30 8
TOTAL EQUITY 88 348 73 045 88 466 73 900
LIABILITIES
Non-current liabilities
Borrowings 8 560 10 387 8 051 10 361
Deferred corporate income tax 1 947 1 640 635 438
Deferred income 2 656 2 099 2 604 2 032
Total Non-Current Liabilities 13 163 14 126 11 290 12 831
Current liabilities
Borrowings 4 258 6 906 3 593 5 700
Trade payables and other liabilities 11 562 12 227 9 677 10 370
Deferred income 800 419 785 402
Total Current Liabilities 16 620 19 552 14 055 16 472
TOTAL LIABILITIES 29 783 33 678 25 345 29 303
TOTAL EQUITY AND LIABILITIES 118 131 106 723 113 811 103 203

 

Statement of comprehensive income Group Parent company
2015 2014 2015 2014
EUR ‘000 EUR ‘000 EUR ‘000 EUR ‘000
Net revenue 97 392 93 654 84 746 81 625
Cost of goods sold (32 315) (29 683) (25 979) (22 791)
Gross Profit 65 077 63 971 58 767 58 834
Selling expense (28 202) (28 356) (23 742) (24 063)
Administrative expense (18 965) (16 198) (18 118) (15 286)
Other operating income 2 715 1 788 2 487 1 274
Other operating expense (1 957) (2 974) (1 864) (3 047)
Share of profit of an associate 118 153
Income from investments in subsidiaries 300
Financial income 262 187 261 183
Financial expense (1 404) (4 728) (1 352) (4 691)
Profit Before Tax 17 644 13 843 16 739 13 204
Corporate income tax (2 110) (2 266) (1 976) (2 247)
Deferred corporate income tax (245) 657 (197) 467
PROFIT FOR THE REPORTING PERIOD 15 289 12 234 14 566 11 424
Other comprehensive income for the reporting period
Total comprehensive income for the reporting period 15 289 12 234 14 566 11 424
Total comprehensive income attributable to:
The equity holders of the Parent Company 15 281 12 237 14 566 11 424
Non-controlling interests 8 (3)
Basic and diluted earnings per share, EUR 1.08 0.87 1.03 0.81

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

read more
Last Year Olainfarm Sets a New Profit Record of 15.3 Million Euros

Sales of Olainfarm in March Reach 9.05 Million Euros

on 15 balandžio, 2016 Komentavimas išjungtas įraše Sales of Olainfarm in March Reach 9.05 Million Euros

According to preliminary consolidated results of JSC Olainfarm for March 2016, sales of company have reached 9.05 million euros, which represents a growth by 4% compared to March 2015. The biggest sales increase has been achieved in Ukraine, where sales grew by 361%. Sales to Turkmenistan grew by 208%, sales to Poland grew by 133%, but sales to Lithuania by 120%. During this period, significant shipments have also been made to Uzbekistan. Major sales markets of JSC Olainfarm in March 2016 were Ukraine, Latvia, Russia and Belarus.

March 2016, consolidated sales Sales, thsnd. EUR Changes to March 2015 Share in total sales
Ukraine 2 494 361% 28%
Latvia 2 222 17% 25%
Russia 1 920 -28% 21%
Belarus 585 -24% 6%
Turkmenistan 316 208% 3%
Uzbekistan 313 NA 3%
The Netherlands 219 -80% 2%
Kazakhstan 180 -60% 2%
Lithuania 173 120% 2%
Poland 155 133% 2%
Other 467 -55% 5%
Total 9 045 4% 100%

 

Sales of pharmacy chain of Latvijas aptieka Ltd. during March 2016 were 1.63 million euros, which represents an increase by 13% compared to the same period of the last year. Sixty-one pharmacies were operating during March this year. Sales of Silvanols Ltd. during March 2016 were 0.44 million euros, which represents an increase by 52% compared to sales made during March 2015. In March 2016, Silvanols Ltd. sold its products in four European countries and with assistance of JSC Olainfarm also to Azerbaijan and Belarus.

In three months of 2016, according to preliminary consolidated results, sales of JSC Olainfarm reached 26.1 million euros, which represents a reduction by 6% compared to three months of 2015. The most rapid sales increase has been achieved in Poland, where sales grew by 181%. Sales to Turkmenistan grew by 162%, sales to Uzbekistan grew by 134% and sales to Belarus grew by 77%. Major sales markets of JSC Olainfarm in three months of 2016 were Latvia, Russia, Ukraine and Belarus.

3 months of 2016, consolidated sales Sales, thsnd. EUR Changes to three months of 2015 Share in total sales
Latvia 6 627 13% 25%
Russia 6 305 -38% 24%
Ukraine 4 860 44% 19%
Belarus 3 027 77% 12%
UK 927 10% 4%
Kazakhstan 569 26% 2%
Turkmenistan 482 162% 2%
Uzbekistan 478 134% 2%
The Netherlands 473 -79% 2%
Poland 386 181% 1%
Other 1 968 -23% 8%
Total 26 101 -6% 100%

 

During the three months period of 2016 sales of pharmacy chain of  Latvijas aptieka Ltd. reached 5.02 million euro, which represents an increase by 19% compared to the same period of 2015. Sales of Silvanols Ltd. in three months of 2016 were 1.22 million euro, which represents an increase by 11% compared to the first quarter of 2015, when sales of Silvanols were 1.1 million euros. Products of Silvanols Ltd. were sold to eight European countries and with assistance of JSC Olainfarm also to Azerbaijan and Belarus.

According to preliminary unconsolidated results, sales of JSC Olainfarm in March 2016 were 7.91 million euros, which represents an increase by 3% compared to the same period of 2015. The biggest sales increase was achieved to Ukraine, where sales grew by 361%. Sales to Italy grew by 287%, sales to Turkmenistan grew by 208%, and sales to Lithuania grew by 159%. Significant shipments during this period were also made to Uzbekistan. Major sales markets of JSC Olainfarm were Ukraine, Russia, Latvia and Belarus. During March 2016, products of JSC Olainfarm were sold to 28 countries in three continents.

March 2016, unconsolidated sales Sales, thsnd. EUR Changes to March, 2015 Share in total sales
Ukraine 2 494 361% 32%
Russia 1 920 -28% 24%
Latvia 1 235 19% 16%
Belarus 585 -24% 7%
Turkmenistan 316 208% 4%
Uzbekistan 313 NA 4%
The Netherlands 219 -80% 3%
Kazakhstan 180 -60% 2%
Lithuania 157 159% 2%
Italy 127 287% 2%
Other 367 -60% 5%
Total 7 911 3% 100%

 

According to unconsolidated preliminary results for three months of 2016, sales of JSC Olainfarm have reached 22.6 million euros, which represents a reduction by 8% compared to the same period of 2015. The most rapid sales increase was achieved in Turkmenistan, where sales grew by 162%. Sales to Uzbekistan grew by 134%, while sales to Belarus and Lithuania grew by 77% each. The major sales markets of JSC Olainfarm in three months of 2016 were Russia, Ukraine, Latvia and Belarus. In three months of 2016, products of JSC Olainfarm were sold to 32 countries in three continents.

3 months of 2016, unconsolidated sales Sales, thsnd. EUR Changes to 3 months of 2015 Share in total sales
Russia 6 305 -38% 28%
Ukraine 4 776 41% 21%
Latvia 3 555 12% 16%
Belarus 3 027 77% 13%
UK 927 10% 4%
Kazakhstan 569 -15% 3%
Turkmenistan 482 162% 2%
Uzbekistan 478 134% 2%
The Netherlands 473 -79% 2%
Lithuania 312 77% 1%
Other 1 698 -7% 8%
Total 22 600 -8% 100%

 

According to preliminary estimates by the management of JSC Olainfarm, unconsolidated sales in 2016 are expected at 90 million euros, while consolidated sales at 103 million euros. According to these preliminary sales results, in three months of 2016, the company has reached 25% of its annual unconsolidated sales estimate and 25% of its annual consolidated sales estimate.

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

read more
Sales of Olainfarm in March Reach 9.05 Million Euros

Sales of Olainfarm in February Reached 8.23 Million Euros

on 15 kovo, 2016 Komentavimas išjungtas įraše Sales of Olainfarm in February Reached 8.23 Million Euros

Preliminary consolidated results of JSC Olainfarm for February 2016 show that sales of the group have reached 8.23 million euros, which represents a reduction by 28% compared to February of 2015. The biggest sales increase was achieved in Uzbekistan, where sales grew by 387%. During February significant shipments have also been made to Tajikistan. The major sales markets of JSC Olainfarm during this period were Latvia, Russia, Ukraine and Belarus.

February 2016, consolidated sales Sales, thsnd. EUR Changes to February 2015 Share in total sales
Latvia 2 282 21% 28%
Russia 2 125 -59% 26%
Ukraine 1 580 -8% 19%
Belarus 923 17% 11%
The Netherlands 255 -59% 3%
Kazakhstan 182 8% 2%
Uzbekistan 165 387% 2%
Tajikistan 135 NA 2%
Lithuania 125 16% 2%
Other 456 -83% 6%
Total 8 226 -28% 100%

 

Sales of pharmacy chain of Latvijas aptieka Ltd. during February 2016 were 1.74 million euro, which represents an increase by 30% compared to February of 2015. Sixty-two pharmacies were operating during this period. Sales of Silvanols Ltd. in February 2016 were 0.47 million euros, which represents an increase by 9% compared to February of 2015. During February of 2016,  Silvanols Ltd. was selling its products to four European countries and with assistance from JSC Olainfarm also to Azerbaijan and Belarus.

According to preliminary consolidated results, sales of the group of JSC Olainfarm during two months of 2016 were 17.06 million euros, which represents a reduction by 11% compared to the same period of 2015. The biggest sales increase during this period was achieved in Poland, where sales grew by 226%. Sales to Belarus increased by 164%, sales to Kazakhstan increased by 75%. During two months of 2016, significant shipments were also made to Germany and Tajikistan. Major sales markets of JSC Olainfarm during two months of 2016 were Latvia, Russia, Belarus, Ukraine and the UK.

2 months of 2016, consolidated sales Sales, thsnd. EUR Changes to 2 months of 2015 Share in total sales
Latvia 4 397 10% 26%
Russia 4 385 -41% 26%
Belarus 2 443 164% 14%
Ukraine 2 366 -17% 14%
UK 893 6% 5%
Kazakhstan 389 75% 2%
The Netherlands 255 -77% 1%
Germany 198 NA 1%
Tajikistan 197 NA 1%
Poland 230 226% 1%
Other 1 307 -22% 8%
Total 17 060 -11% 100%

 

During two months of 2016, sales of Latvijas aptieka Ltd. reached 3.4 million euros, which represents an increase by 21% compared to the same period one year ago. Sales of Silvanols Ltd. during two months of this year were 0.79 million euros, which represents a reduction by 4% compared to the same period of 2015, where this company made sales of 0.82 million euros. During two months of 2016, products of Silvanols Ltd. were sold to eight European countries and with the help of JSC Olainfarm also to Azerbaijan and Belarus.

According to unconsolidated preliminary results for February 2016, sales of JSC Olainfarm during this period were 6.93 million euros, which represents a reduction by 33% compared to the same period of 2015. The biggest sales increases were achieved in Uzbekistan, where sales grew by 387% and Lithuania, where sales grew by 65%. During February 2016, JSC Olainfarm also made significant shipments to Tajikistan. Major sales markets during this period were Russia, Ukraine, Latvia and Belarus. Products of JSC Olainfarm were sold to 24 countries on three continents.

February 2016, unconsolidated sales Sales, thsnd. EUR Changes to February 2015 Share in total sales
Russia 2 125 -59% 31%
Ukraine 1 496 -13% 22%
Latvia 1 127 19% 16%
Belarus 923 17% 13%
The Netherlands 255 -59% 4%
Kazakhstan 182 8% 3%
Uzbekistan 165 387% 2%
Tajikistan 135 NA 2%
Lithuania 108 65% 2%
Other 413 -46% 6%
Total 6 927 -33% 100%

 

According to preliminary unconsolidated results, sales of JSC Olainfarm in two months of 2016 were 14.68 million euros, which represents a reduction by 13% compared to the respective period of 2015. The most rapid sales increases during two months of this year were achieved in Belarus, where sales grew by 164%, and Kazakhstan where sales grew by 75%. During two months of 2016 significant shipments were also made to Germany, Tajikistan and Poland. Major sales markets of JSC Olainfarm during two months of 2016 were Russia, Belarus, Latvia, and the UK. In total, during two months of 2016, products of JSC Olainfarm were sold to 30 countries on three continents.

2 months of 2016, unconsolidated sales Sales, thsnd. EUR Changes to 2 months of 2015 Share in total sales
Russia 4 385 -41% 30%
Belarus 2 443 164% 17%
Latvia 2 313 9% 16%
Ukraine 2 282 -20% 16%
UK 893 6% 6%
Kazakhstan 389 75% 3%
The Netherlands 255 -77% 2%
Germany 198 NA 1%
Tajikistan 197 NA 1%
Poland 180 NA 1%
Other 1 145 -10% 8%
Total 14 679 -13% 100%

 

In accordance with preliminary estimates by JSC Olainfarm, unconsolidated sales of the company in 2016 might reach 90 million euros, while consolidated sales of the group could be as high as 103 million euros. According to these preliminary sales figures, in two months of 2016, 17% of annual target for unconsolidated sales and 16% of annual target for consolidated sales have been achieved.

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

 

read more
Sales of Olainfarm in February Reached 8.23 Million Euros

Recording of the Investor Conference Webinar about financial results of 2015

on 14 kovo, 2016 Komentavimas išjungtas įraše Recording of the Investor Conference Webinar about financial results of 2015

On March 14 JSC Olainfarm organized its Investor Conference Online Webinar. During the webinar the member of the management board of JSC Olainfarm Salvis Lapiņš analyzed the financial results of fourth quarter 2015 and non-audited financial results of 12 months 2015, as well as informed about the other recent activities within the company.

During the presentation Salvis Lapiņš noted that JSC Olainfarm intends to pay dividends for 2015 and next few years, however considering the recent and planned acquisitions the proposal from the management board of JSC Olainfarm currently is to freeze the payout ratio at 15% for next three years.

The recorded Olainfarm webinar is available online: ej.uz/OLF_YE2015_video, and the presentation, demonstrated during the webinar, is available here: Webinar Presentation: 4th quarter and the whole 2015

Olainfarm thanks all participants, who joined the webinar, and encourages everybody to follow company’s announcements to get information on the next webinar!

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

read more
Recording of the Investor Conference Webinar about financial results of 2015